BIOGEN INC. DL -,0005 | 230.450 / 0.00% |
Date/Time | 01/16 / 12:06 |
Chg. / Chg.(%) | 0.000 / 0.00% |
Bid | 230.450 |
Ask | 231.650 |
Open | 230.450 |
Previous Close | 230.450 |
High | 230.450 |
Low | 230.450 |
Volume [EUR] | - |
Volume [Units] | |
Price fixings | 7 |
ISIN | US09062X1037 |
Security | IDP |
Exchange | Lang & Schwarz |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 230.450 | ![]() |
|
NASDAQ | 275.8400 | ![]() |
1,765,034 |
IEX | 276.10 | ![]() |
119,032 |
Cboe US | 276.02 | ![]() |
113,485 |
London Inter.. | 277.76 | ![]() |
9,322 |
TradeGate | 228.200 | ![]() |
2,095 |
Xetra | 230.75 | ![]() |
1,973 |
Mexico | 5,488.00 | ![]() |
758 |
Stuttgart | 228.950 | ![]() |
599 |
Frankfurt | 228.7500 | ![]() |
385 |
Vienna Globa.. | 231.30 | ![]() |
367 |
gettex | 229.650 | ![]() |
67 |
Hamburg | 230.60 | ![]() |
20 |
Düsseldorf | 230.10 | ![]() |
12 |
München | 229.25 | ![]() |
0 |
Berlin | 230.00 | ![]() |
0 |
Hannover | 231.15 | ![]() |
0 |
News
- Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
01/11/2021 / 13:30 - GlobeNewswire - Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
01/08/2021 / 13:30 - GlobeNewswire - The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
12/21/2020 / 13:30 - GlobeNewswire - Biogen agrees to $22M settlement to resolve claims on illegal business
12/17/2020 / 20:04 - TeleTrader - Biogen Files New Drug Application for Aducanumab in Japan
12/10/2020 / 04:30 - GlobeNewswire